Compounds and compositions for intracellular delivery of agents
The disclosure features amino lipids and compositions involving the same. Nanoparticle compositions include an amino lipid as well as additional lipids such as phospholipids, structural lipids, PEG lipids, or a combination thereof. Nanoparticle compositions further including therapeutic and/or prophylactic agents such as RNA are useful in the delivery of therapeutic and/or prophylactic agents to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
1. A compound selected from:
and salts thereof.
2. A nanoparticle composition comprising a lipid component comprising a compound according to claim 1 .
3. The nanoparticle composition of claim 2 , wherein the lipid component further comprises a polyethylene glycol (PEG) lipid of Formula (VI):
or a salt or isomer thereof, wherein:
R 3PEG is —OR O ;
R O is hydrogen, C 1-5 alkyl or an oxygen protecting group;
r is an integer between 1 and 100;
R 5PEG is C 10-40 alkyl, C 10-40 alkenyl, or C 10-40 alkynyl; and optionally one or more methylene groups of R5PEG are independently replaced with C 3-10 carbocyclylene, 4 to 10 membered heterocyclylene, C 6-10 arylene, 4 to 10 membered heteroarylene, —N(R N )—, —O—, —S—, —C(O)—, —C(O)N(R N )—, —NR N C(O)—, —NR N C(O)N(R N )—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(R N )—, —NR N C(O)O—, —C(O)S—, —SC(O)—, —C(═NR N )—, —C(═NR N )N(R N )—, —NR N C(═NR N )—, —NR N C(═NR N )N(R N )—, —C(S)—, —C(S)N(R N )—, —NR N C(S)—, —NR N C(S)N(R N )—, —S(O)—, —OS(O)—, —S(O)O—, —OS(O)O—, —OS(O) 2 —, —S(O) 2 O—, —OS(O) 2 O—, —N(R N )S(O)—, —S(O)N(R N )—, —N(R N )S(O)N(R N )—, —OS(O)N(R N )—, —N(R N )S(O)O—, —S(O) 2 —, —N(R N )S(O) 2 —, —S(O) 2 N(R N )—, —N(R N )S(O) 2 N(R N )—, —OS(O) 2 N(R N )—, or —N(R N )S(O) 2 O—; and
each instance of R N is independently hydrogen, C 1-6 alkyl, or a nitrogen protecting group.
4. The nanoparticle composition of claim 2 , wherein the lipid component further comprises a phospholipid.
5. The nanoparticle composition of claim 4 , wherein the phospholipid is selected from the group consisting of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine,1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), sphingomyelin, and mixtures thereof.
6. The nanoparticle composition of claim 2 , wherein the lipid component further comprises a structural lipid.
7. The nanoparticle composition of claim 6 , wherein the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof.
8. The nanoparticle composition of claim 2 , wherein the lipid component comprises about 30 mol % to about 60 mol % of any one of compounds 150 to 161, and further comprises about 0 mol % to about 30 mol % phospholipid, about 18.5 mol % to about 48.5 mol % structural lipid, and about 0 mol % to about 10 mol % PEG lipid.
9. The nanoparticle composition of claim 2 , further comprising a therapeutic and/or prophylactic agent.
10. The nanoparticle composition of claim 9 , wherein the therapeutic and/or prophylactic agent is an mRNA.
11. A pharmaceutical composition comprising the nanoparticle composition of 10 and a pharmaceutical carrier.
12. A method of producing a polypeptide of interest in a mammalian cell, the method comprising contacting the cell with the nanoparticle composition of claim 10 , wherein the mRNA encodes the polypeptide of interest, whereby the mRNA is capable of being translated in the cell to produce the polypeptide of interest.
13. A method of specifically delivering a therapeutic and/or prophylactic agent to a mammalian organ, the method comprising administering to a mammal the nanoparticle composition of claim 10 , said administering comprising contacting the mammalian organ with the nanoparticle composition, whereby the therapeutic and/or prophylactic agent is delivered to the organ.